Advanced glycation endproducts in chronic heart failure

Annals of the New York Academy of Sciences

Volumn 1126, Issue , 2008, Pages 225-230

  Smit, Andries J ^a   Hartog, Jasper W L ^a   Voors, Adriaan A ^a   Van Veldhuisen, Dirk J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Advanced glycation endproducts; Heart failure; Renal function

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; CALCIUM; RECEPTOR;

ARTERIAL STIFFNESS; AUTOFLUORESCENCE; BIOACCUMULATION; BLOOD LEVEL; CALCIUM TRANSPORT; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; CROSS LINKING; DIABETES MELLITUS; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART MUSCLE; HEART MUSCLE COMPLIANCE; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY PERFUSION; NONHUMAN; PATHOGENESIS; PROGNOSIS; PROTEIN INTERACTION; SYSTOLIC HEART FAILURE; TISSUE LEVEL; VASCULAR ENDOTHELIUM;

EID: 42549145384     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1433.038     Document Type: Conference Paper

References (35)

1. 1 Levy, D., S. Kenchaiah, M.G. Larson, et al. 2002. Long‐term trends in the incidence of and survival with heart failure. N. Engl. J. Med. 347: 1397–1402.
2. 2 Virga, G., B. Stomaci, A. Munaro, et al. 2006. Systolic and diastolic function in renal replacement therapy: a cross‐sectional study. J. Nephrol. 19: 155–160.
3. 3 Schafer, S., J. Huber, C. Wihler, et al. 2006. Impaired left ventricular relaxation in type 2 diabetic rats is related to myocardial accumulation of N(epsilon)‐(carboxymethyl) lysine. Eur. J. Heart Fail. 8: 2–6.
4. 4 Aronson, D. 2003. Cross‐linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J. Hypertens 21: 3–12.
5. 5 Aronow, W.S. & C. Ahn. 1999. Incidence of heart failure in 2,737 older persons with and without diabetes mellitus. Chest 115: 867–868
6. 6 Galderisi, M., K.M. Anderson, P.W. Wilson & D. Levy. 1991. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy. Am. J. Cardiol. 68: 85–89.
7. 7 Galderisi, M. 2006. Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler echocardiography. J. Am. Coll. Cardiol. 48: 1548–1551.
8. 8 Boudina, S. & D. Abel. 2007. Diabetic cardiomyopathy revisited. Circulation 115: 3213–3223.
9. 9 Hartog, J.W.L., A.A. Voors, S.J.L. Bakker, et al. 2007. Advanced Glycation end‐products (AGEs) and heart failure: pathophysiology and clinical implications. Eur. J. Heart. Fail., 9: 1146–1155.
10. 10 Vaitkevicius, P.V., M. Lane & H. Spurgeon. 2001. A cross‐link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc. Natl. Acad. Sci. USA 98: 1171–1175.
11. 11 Smit, A.J. & H.L. Lutgers. 2004. The clinical relevance of advanced glycation endproducts and recent developments in pharmaceutics to reduce AGE accumulation. Curr. Med. Chem. 11: 2767–2784.
12. 12 Striker, L.J. & G.E. Striker. 1996. Administration of AGEs in vivo induces extracellular matrix gene expression. Nephrol. Dial. Transpl. 11: S62–S65.
13. 13 Petrova, R., Y. Yamamoto, K. Muraki, et al. 2002. Advanced glycation endproduct‐induced calcium handling impairment in mouse cardiac myocytes. J. Mol. Cell Card. 34: 1425–1431.
14. 14 Smith, G.L., J.H. Lichtman, M.B. Bracken, et al. 2006. Renal impairment and outcomes in heart failure: systematic review and meta‐analysis. J. Am. Coll. Cardiol. 47: 1987–1996.
15. 15 Smilde, T.D., D.J. Van Veldhuisen, G. Navis, et al. 2006. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation 114: 1572–1580.
16. 16 Little, W.C., M.R. Zile, D.W. Kitzman, et al. 2005. The effect of alagebrium chloride (ALT‐711), a novel glucose cross‐link breaker, in the treatment of elderly patients with diastolic heart failure. J. Card Fail. 11: 191–195.
17. 17 Thohan, V., M.M. Koerner, C.M. Pratt & G.A. Torre. 2005. Improvements in diastolic function among patients with advanced systolic heart failure utilizing alagebrium (an oral advanced glycation end‐product cross‐link breaker). Circulation 112 (Suppl 2): 2647.
18. 18 Norton, G.R., G. Candy & A.J. Woodiwiss. 1996. Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin‐induced diabetes mellitus in rats. Circulation 93: 1905–1912.
19. 19 Avendano, G.F., R.K. Agarwal, R.I. Bashey, et al. 1999. Effects of glucose intolerance on myocardial function and collagen‐linked glycation. Diabetes 48: 1443–1447.
20. 20 Asif, M., J. Egan, S. Vasan, et al. 2000. An advanced glycation endproduct cross‐link breaker can reverse age‐related increases in myocardial stiffness. Proc. Natl. Acad. Sci. USA 97: 2809–2813.
21. 21 Berg, T.J., O. Snorgaard, J. Faber, et al. 1999. Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care 22: 1186–1190.
22. 22 Heidland, A., K. Sebekova, A. Frangiosa, et al. 2004. Paradox of circulating AGE concentrations in patients with CHF and after heart transplantation. Heart 90: 1269–1274.
23. 23 Steine, K., J. Larsen, M. Stugaard, et al. 2007. LV systolic impairment in patients with asymptomatic coronary heart disease and type 1 diabetes is related to coronary atherosclerosis, glycaemic control and advanced glycation endproducts. Eur. J. Heart Failure 9: 1044–1050.
24. 24 Koyama, Y., Y. Takeishi & T. Arimoto. High serum level of pentosidine, an advanced glycation end product, is a risk factor of patients with heart failure. J. Card. Fail. 13: 199–206.
25. 25 Hartog, J.W.L., A.A. Voors, C.G. Schalkwijk, et al. 2007. Clinical and prognostic value of advanced glycation end‐products in chronic heart failure. Eur. Heart J, 28: 2879–2885.
26. 26 Meerwaldt, R., R. Graaff, P. Oomen, et al. 2004. Simple non‐invasive assessment of advanced glycation endproduct accumulation. Diabetologia 47: 1324–1330.
27. 27 Jadoul, M., Y. Ueda, Y. Yasuda, et al. 1999. Influence of hemodialysis membrane type on pentosidine plasma level, a marker of “carbonyl stress”. Kidney Int. 55: 2487–2492.
28. 28 Schwedler, S.B., T. Metzger, R. Schinzel & C. Wanner. 2002. Advanced glycation end products and mortality in hemodialysis patients. Kidney Int. 62: 301–310.
29. 29 Busch, M., S. Franke, G. Wolf, et al. 2006. The advanced glycation end product N(epsilon)‐carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension. Am. J. Kidney Dis. 48: 571–579.
30. 30 Wagner, Z., M. Molnar, G.A. Molnar, et al. 2006. Serum carboxymethyllysine predicts mortality in hemodialysis patients. Am. J. Kidney Dis. 47: 294–300.
31. 31 Roberts, M.A., M.C. Thomas, D. Fernando, et al. 2006. Low molecular weight advanced glycation end products predict mortality in asymptomatic patients receiving chronic haemodialysis. Nephrol. Dial. Transplant. 21: 1611–1617.
32. 32 Meerwaldt, R., J. Hartog, R. Graaff, et al. 2005. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J. Am. Soc. Nephrol. 16: 3687–3693.
33. 33 Meerwaldt, R., H.L. Lutgers, T.P. Links, et al. 2007. Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 30: 107–112.
34. 34 Kilhovd, B., A. Juutilainen, S. Lehto, et al. 2005. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population‐based 18‐year follow‐up study. Art. Thromb. Vasc. Biol. 25: 815–820.
35. 35 Miyata, T. & S. Van Ypersele. 2003. Angiotensin II receptor blockers and angiotensin converting enzyme inhibitors: implication of radical scavenging and transition metal chelation in inhibition of advanced glycation end product formation. Arch. Biochem. Biophys. 419: 50–54.